About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Cardiovascular Diseases group is a translational research group within the Cardiology Department of Vall d’Hebron Hospital that performs laboratory, clinical and epidemiological research. In the CIBERCV network we are within the topic of descriptor 2 “Arterial disease, thrombosis and myocardial ischemia-reperfusion injury”. Our contributions in these topics address the following lines:
In the CIBERESP network, our group is interested in the study of effectiveness/cost-effectiveness of cardiovascular interventions, health outcome research and methods in clinical research. The group has 19 principal investigators, 32 active projects and clinical trial and has been done 142 publications in 2020.
IP: - Collaborators: Miriam Izquierdo Sans Funding agency: Instituto de Salud Carlos III Funding: 82400 Reference: FI16/00390 Duration: 01/03/2017 - 31/07/2021
IP: - Collaborators: Miriam Izquierdo Sans Funding agency: European Society of Cardiology (ESC) Funding: 25000 Reference: ESC/EARLY.CAREER/2016/ILARIA Duration: 12/09/2016 - 11/09/2017
IP: - Collaborators: The effect of intracoronary reinfusion of bone marrow-derived mononuclear cells (BM-MNC) on all cause mortality in acute myocard Funding agency: EUROPEAN COMMISSION Funding: 154191.92 Reference: BAMI_FP7HEALTH2011 Duration: 01/11/2011 - 31/10/2017
IP: Jose Fernando Rodríguez Palomares Collaborators: Inmaculada Fuentes Camps, Olga Sánchez- Maroto Carrizo, Filipa Xavier De Carvalho Negrao Valente Funding agency: EUROPEAN COMMISSION Funding: 155080 Reference: DISCHARGE_FP7HEALTH2013 Duration: 01/02/2014 - 31/01/2020
A study led by the Vall d'Hebron Research Institute (VHIR) demonstrates the causal role of air pollution in ventricular arrhythmias and identifies a possible therapeutic strategy based on antioxidants.
The grants, amounting to more than €533,000 for VHIR, will allow clinical duties to be partially released over three years to promote strategic research projects in obesity, respiratory diseases, aortic pathology and metabolic fatty liver disease.
Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research
Echocardiography Rates
PDF 0.66 MB
Hemodynamics Rates
PDF 0.47 MB
